Should You Buy Erasca Inc (ERAS) Stock on Friday?

Erasca Inc (ERAS) stock is higher by 13.20% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Erasca Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ERAS!

See Full ERAS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ERAS Stock Today?

Erasca Inc (ERAS) stock is trading at $2.23 as of 12:13 PM on Friday, Oct 6, a gain of $0.11, or 4.95% from the previous closing price of $2.12. The stock has traded between $2.09 and $2.23 so far today. Volume today is below average. So far 184,046 shares have traded compared to average volume of 619,196 shares. To screen for more stocks like Erasca Inc click here.

More About Erasca Inc

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Click Here to get the full Stock Report for Erasca Inc stock.